This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Joseph, I. B. J. K. Articles by Isaacs, J. T. Search for Related Content PubMed PubMed Citation Articles by Joseph, I. B. J. K. Articles by Isaacs, J. T.

Potentiation of the Antiangiogenic Ability of Linomide by Androgen Ablation Involves Down-Regulation of Vascular Endothelial Growth Factor in Human Androgen-responsive Prostatic Cancers¹

Johns Hopkins Oncology Center [I. B. J. K. J., J. T. I.] and Department of Urology [J. T. I.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Linomide is a p.o. active antiangiogenic agent that has been demonstrated to be effective in suppressing the in vivo growth of rat and human prostatic cancer xenografts. The present studies were conducted to determine whether the angiogenic molecules, vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) and basic fibroblast growth factor (bFGF) are expressed in vitro by DU-145, PC-3, TSU-PR1, and LnCaP human prostate cancer cell lines and whether Linomide inhibits the secretion of these angiogenic molecules. Additionally, two different androgen-responsive human prostatic cancer xenograft models (i.e., PC-82 and A-2) were used to determine whether androgen ablation-induced reduction in tumor growth is associated with a reduction in tumor VEGF and/or bFGF levels. These studies demonstrated that both VEGF and bFGF proteins are expressed to different degrees in the human prostatic cancer cell lines. The secretion of BEGF but not bFGF is up-regulated by hypoxia. Linomide is unable to inhibit either basal or hypoxia-induced secretion of VEGF. Linomide also has no effect on secreted bFGF levels. Castration inhibited tumor VEGF but had no effect on bFGF levels in both the androgen-responsive PC-82 and A-2 human prostatic cancers when grown in severe combined immunodeficient mice. When given in combination, castration potentiated the inhibition of tumor growth induced by Linomide alone. This potentiation is not due to a further inhibition in tumor VEGF levels induced by castration. Although both castration and Linomide inhibit angiogenesis, the former accomplishes it by inhibiting VEGF secretion, whereas the latter has multiple effects at several steps in the angiogenic process other than VEGF secretion. Based on their different but complementary mechanisms of action, simultaneous combination of androgen ablation with Linomide enhances the anti-prostatic cancer efficacy compared to either monotherapies alone and warrants testing in humans.

¹ Supported by NIH Grant CA 62482.

² To whom requests for reprints should be addressed, at Johns Hopkins Oncology Center, 422 North Bond Street, Baltimore, MD 21231.

Received 11/26/96. Accepted 2/ 1/97.

This article has been cited by other articles:

				R. Zhai, G. Liu, W. Zhou, L. Su, R. S. Heist, T. J. Lynch, J. C. Wain, K. Asomaning, X. Lin, and D. C. Christiani Vascular Endothelial Growth Factor Genotypes, Haplotypes, Gender, and the Risk of Non-Small Cell Lung Cancer Clin. Cancer Res., January 15, 2008; 14(2): 612 - 617. [Abstract] [Full Text] [PDF]

				M. Colombel, S. Filleur, P. Fournier, C. Merle, J. Guglielmi, A. Courtin, A. Degeorges, C. M. Serre, R. Bouvier, P. Clezardin, et al. Androgens Repress the Expression of the Angiogenesis Inhibitor Thrombospondin-1 in Normal and Neoplastic Prostate Cancer Res., January 1, 2005; 65(1): 300 - 308. [Abstract] [Full Text] [PDF]

				B. Nicholson, K. Gulding, M. Conaway, S. R. Wedge, and D. Theodorescu Combination Antiangiogenic and Androgen Deprivation Therapy for Prostate Cancer: A Promising Therapeutic Approach Clin. Cancer Res., December 15, 2004; 10(24): 8728 - 8734. [Abstract] [Full Text] [PDF]

				D. B. Martin, D. R. Gifford, M. E. Wright, A. Keller, E. Yi, D. R. Goodlett, R. Aebersold, and P. S. Nelson Quantitative Proteomic Analysis of Proteins Released by Neoplastic Prostate Epithelium Cancer Res., January 1, 2004; 64(1): 347 - 355. [Abstract] [Full Text] [PDF]

				W. D. Fox, B. Higgins, K. M. Maiese, M. Drobnjak, C. Cordon-Cardo, H. I. Scher, and D. B. Agus Antibody to Vascular Endothelial Growth Factor Slows Growth of an Androgen-independent Xenograft Model of Prostate Cancer Clin. Cancer Res., October 1, 2002; 8(10): 3226 - 3231. [Abstract] [Full Text] [PDF]

				C. M. Benning and N. Kyprianou Quinazoline-derived {alpha}1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis Via an {alpha}1-Adrenoceptor-independent Action Cancer Res., January 1, 2002; 62(2): 597 - 602. [Abstract] [Full Text] [PDF]

				K. A. Olson, H. R. Byers, M. E. Key, and J. W. Fett Prevention of Human Prostate Tumor Metastasis in Athymic Mice by Antisense Targeting of Human Angiogenin Clin. Cancer Res., November 1, 2001; 7(11): 3598 - 3605. [Abstract] [Full Text] [PDF]

				J. Gao, J. T. Arnold, and J. T. Isaacs Conversion from a Paracrine to an Autocrine Mechanism of Androgen-stimulated Growth during Malignant Transformation of Prostatic Epithelial Cells Cancer Res., July 1, 2001; 61(13): 5038 - 5044. [Abstract] [Full Text] [PDF]

				J. I. Izawa and C. P.N. Dinney The role of angiogenesis in prostate and other urologic cancers: a review Can. Med. Assoc. J., March 1, 2001; 164(5): 662 - 670. [Abstract] [Full Text] [PDF]

				D. J. Gross, I. Reibstein, L. Weiss, S. Slavin, I. Stein, M. Neeman, R. Abramovitch, and L. E. Benjamin The Antiangiogenic Agent Linomide Inhibits the Growth Rate of von Hippel-Lindau Paraganglioma Xenografts to Mice Clin. Cancer Res., November 1, 1999; 5(11): 3669 - 3675. [Abstract] [Full Text] [PDF]

				I. B. J. K. Joseph and J. T. Isaacs RESPONSE: Re: Macrophage Role in the Anti-Prostate Cancer Response to One Class of Antiangiogenic Agents J Natl Cancer Inst, May 5, 1999; 91(9): 805 - 806. [Full Text] [PDF]

				B. B. Moore, D. A. Arenberg, K. Stoy, T. Morgan, C. L. Addison, S. B. Morris, M. Glass, C. Wilke, Y. Y. Xue, S. Sitterding, et al. Distinct CXC Chemokines Mediate Tumorigenicity of Prostate Cancer Cells Am. J. Pathol., May 1, 1999; 154(5): 1503 - 1512. [Abstract] [Full Text] [PDF]

				M. D. Balbay, C. A. Pettaway, H. Kuniyasu, K. Inoue, E. Ramirez, E. Li, I. J. Fidler, and C. P. N. Dinney Highly Metastatic Human Prostate Cancer Growing within the Prostate of Athymic Mice Overexpresses Vascular Endothelial Growth Factor Clin. Cancer Res., April 1, 1999; 5(4): 783 - 789. [Abstract] [Full Text] [PDF]

				A. C. Levine, X.-H. Liu, P. D. Greenberg, M. Eliashvili, J. D. Schiff, S. A. Aaronson, J. F. Holland, and A. Kirschenbaum Androgens Induce the Expression of Vascular Endothelial Growth Factor in Human Fetal Prostatic Fibroblasts Endocrinology, November 1, 1998; 139(11): 4672 - 4678. [Abstract] [Full Text] [PDF]